Get the latest stock market update with Mary Ellen McGonagle. Learn key downside signals, how to manage pullbacks, and which earnings reports could impact the market next week.
In this week’s episode, Mary Ellen reviews where the markets currently stand and what to watch for to signal further downside. She also highlights ways to combat inevitable pullbacks and shares the key earnings reports that are likely to move the markets in the upcoming week.
New videos from Mary Ellen premiere weekly on Fridays. You can view all previously recorded episodes at this link.
If you’re looking for stocks to invest in, be sure to check out the MEM Edge Report! This report gives you detailed information on the top sectors, industries and stocks so you can make informed investment decisions.
Confused by mixed market signals? Follow along as Julius analyzes sector rotation, asset rotation, and global market trends using daily and weekly Relative Rotation Graphs (RRGs).
In this video, Julius puts the current sector rotation in perspective on both weekly and daily Relative Rotation Graphs (RRGs). He also examines asset rotation and the position of the U.S. markets in relation to international equities.
This video was originally published on May 27, 2025. Click on the icon above to view on our dedicated page for Julius.
In this video, Chip Anderson, President of StockCharts, sits down with Tony for a conversation in the StockCharts studio! During this in-depth Q&A session, Chip and Tony explore the powerful features that make the OptionsPlay add-on a must-have for options traders using the StockCharts platform. They discuss the integration of the StockCharts Scanning Engine with OptionsPlay strategies—showcasing how this tool enhances your ability to find trade setups quickly and effectively.
In this must-see market update, Larry Williams returns with timely stock market analysis, trading insights, and macroeconomic forecasts. Discover what’s next for the Federal Reserve, interest rates, and inflation — and how it could impact top stocks like Tesla (TSLA), Nvidia (NVDA), Apple (AAPL), and consumer staples (XLP).
Larisa Sprott of Sprott Money and Argo shares her thoughts on the gold and silver markets, saying she sees the ‘smart money’ continuing to gravitate toward these metals.
In her view, price dips present a chance to get in at lower levels.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.
According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.
This condition affects more than 7 million people in the US alone; it’s also the most common form of dementia and is the seventh leading cause of death in America. Treatments are available to alleviate Alzheimer’s disease symptoms, but there are currently none that affect the underlying causes of this neurodegenerative disease.
Alzheimer’s disease therapies that have been approved by the US Food and Drug Administration (FDA) include: rivastigmine by Novartis (NYSE:NVS); galantamine, developed by Janssen, a division of Johnson & Johnson (NYSE:JNJ); donepezil by Pfizer (NYSE:PFE); and memantine by AbbVie (NYSE:ABBV).
Since there is no cure for Alzheimer’s disease, death is often the result for patients as the ailment causes brain deterioration. And unfortunately, Alzheimer’s disease is rising in prevalence — a report from Grand View Research suggests that the global Alzheimer’s disease treatment market will be worth a significant US$15.57 billion by 2030 as more patients need treatment, and as more investments are made in biomarkers for diagnosis and drug development.
The first NASDAQ-listed Alzheimer’s drug company on this list is Massachusetts-based Biogen, a pioneer in the field of neuroscience. The firm is focused on developing, manufacturing and marketing therapies aimed at treating serious neurological, neurodegenerative, autoimmune and rare diseases.
The global biotechnology firm’s research areas include Alzheimer’s disease and dementia. However, the launch of Biogen’s FDA-approved Alzheimer’s disease drug Aduhelm faced a lot of pushback in 2022, both from the market and from Congress, over what was viewed as a hasty fast-track approval process and exorbitant costs to patients.
Biogen gave it another go with Leqembi (lecanemab-irmb), its amyloid-beta monoclonal antibody for the treatment of Alzheimer’s disease, which the FDA approved in 2023 under its accelerated approval pathway. The drug was jointly developed by Biogen and Tokyo-based pharmaceutical company Eisai (OTC Pink:ESALF,TSE:4523). It is for patients with mild cognitive impairment or mild dementia, and is the first drug shown to slow the progression of Alzheimer’s disease to win FDA approval.
In January 2025, Leqembi received another FDA approval, this time for intravenous maintenance dosing for early-stage Alzheimer’s. Later, in April, the European Commission granted Leqembi Marketing Authorization in the EU for the treatment of mild early-stage Alzheimer’s disease.
That same month, the FDA granted fast track designation to Biogen’s investigational tau-targeting therapy BIIB080 for the treatment of Alzheimer’s.
Biogen’s earnings report for Q1 shows that first quarter global in-market sales of Leqembi reached approximately US$96 million, including US in-market sales of approximately US$52 million.
2. Acadia Pharmaceuticals (NASDAQ:ACAD)
Market cap: US$3.68 billion Share price: US$21.98
Acadia Pharmaceuticals specializes in neuroscience and neuro-rare diseases. The biotech’s product portfolio includes the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, as well as the first and only approved drug in the United States and Canada for the treatment of Rett syndrome.
Acadia’s clinical-stage pipeline includes drug candidates targeting Prader-Willi syndrome and Alzheimer’s disease psychosis.
The company expects to enroll its final patient in its RADIANT Phase 2 study of ACP-204 in Alzheimer’s disease psychosis by early 2026 and release topline data in mid-2026.
According to the company, there are currently no approved treatments for hallucinations and delusions associated with Alzheimer’s disease psychosis.
3. Anavex Life Sciences (NASDAQ:AVXL)
Market cap: US$642.85 million Share price: US$7.53
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative, neurodevelopmental and neuropsychiatric disorders, such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome and other central nervous system disorders.
Anavex’ lead drug candidate, Anavex 2-73 (blarcamesine), has successfully completed Phase 2a and a Phase 2b/3 clinical trials for Alzheimer’s disease.
In early January, the company announced positive topline safety and efficacy data from more than three years of continuous treatment with blarcamesine for early Alzheimer’s disease patients. Later that month, Anavex announced it had been issued a US patent for the treatment.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Challenger Gold Limited (ASX: CEL) (‘CEL’ or the ‘Company’) is pleased to announce it has entered into an Investment Protection Agreement (“IPA” or “the Agreement”) with the Government of Ecuador for its 100% owned El Guayabo Project (“El Guayabo” or “the Project”). Under the terms of the IPA, the Government of Ecuador has granted CEL legal protections including stability of the regulatory framework, resolution of disputes through international arbitration, and protection of CEL’s investment.
The IPA covers US$75 million in investment from CEL encompassing expenditures from CEL’s initial acquisition of the project in 2019 and expenditure incurred until the end of 2027. It has an initial term of 8 years and is renewable. Key incentives and protections under the IPA include:
Regulatory stability and protection from changes to the current legal framework
The legal framework at the time of execution will continue to apply if the terms are more favourable to the project owner than any potential new framework
The IPA guarantees rights including non-discriminatory treatment, property protection, and legal certainty
International arbitration, should there be any disputes in relation to the Project, with the seat of arbitration in London under the rules of the International Chamber of Commerce
Commenting on the Investment Protection Agreement, CEL Managing Director, Mr Kris Knauer, said
“The completion of the Investment Protection Agreement is a significant development for the Project..
The IPA provides certainty with respect to the legal framework governing the Project, including stable mining regulations and fiscal terms, and security of title and investment for the term of the agreement. Additionally, it provides protection from all forms of confiscation and a mechanism for international arbitration should there be any disputes related to the project.
The IPA is also timely given recent corporate action in Ecuador as we take steps to monetise our Ecuador assets following the significant resource upgrade from 4.5 million ounce1 to 9.1 million ounces1,2,3.‘
McLaren Minerals Limited (ASX: MML) (‘McLaren’ or ‘Company’), is pleased to provide a further update on the phase 1 Drill Program at its wholly owned McLaren Titanium Project in the western Eucla Basin, Western Australia. This update is driven by the completion of geological interpretation of all the drilling during this campaign, in the absence of laboratory results.
Highlights
McLaren Titanium Project
192 drill holes completed for a total of 4,067 metres, on time and without incident
Significant extensions of prospective sediments outside of currently known resource boundaries observed during drilling:
North extension: approximately 2,200m wide, avg. 14m thick (max 23m),
Central zone eastern extension: 800m wide, avg. 20m thick (max 23m),
Metallurgical and geological samples submitted to IHC and Diamantina Laboratories
Geological work has improved confidence in deposit morphology and is expected to reduce future drilling costs
Strong community support confirmed within an established mining region
McLaren Mineral Sands Managing Director, Simon Finnis, commented:
“While we have not yet received any assays, phase 1 has delivered strong confidence to our team regarding this project. The most recent interpretation not only confirm the integrity of our geological model, but importantly, demonstrates the scale of the opportunity ahead. Defining substantial potential for mineralisation outside the current Resource boundary positions us well for future resource growth. We’ve also made solid ground operationally—drilling was completed on time, we’ve brought costs down, and we’re seeing strong local support. Taken together, these outcomes give us a great deal of confidence as we move toward the next phase of work and continue building long-term value for shareholders.”
Walmart agreed to pay a small fine and promised to ensure its third-party resellers are unable to sell realistic looking toy guns to buyers in New York, after state Attorney General Letitia James said Tuesday that the retail giant’s online store shipped them to the state.
The settlement comes nearly a decade after Walmart, Amazon, Sears and other retailers entered into a consent order and judgment with New York’s previous attorney general, in which they agreed to keep toy guns that resemble actual deadly weapons off their shelves statewide and they paid civil penalties that topped $300,000.
The 2015 order was part of a nationwide reckoning over realistic looking toy guns in the wake of the fatal shooting of Tamir Rice, a 12 year-old Cleveland boy who was killed by police in November 2014 while holding a pellet gun.
The New York law bans retailers from selling or shipping toy guns of certain colors — black, dark blue, silver, or aluminum — that look like real weapons.
A realistic-looking toy gun Walmart shipped to New York.New York Attorney General’s Office
Toy guns sold in the state must be “made in bright colors or made entirely of transparent or translucent materials,” with businesses subject to a fine of $1,000 per violation, according to James’ office.
James said on Tuesday that an investigation by her office found that Walmart’s online store had shipped at least nine realistic-looking toy guns sold by third-party sellers to New York City, Westchester County and Western New York.
But the investigation also found that between March 2020 and November 2023, at least 46 imitation weapons that violate New York state law were purchased by consumers in the state through the Walmart.com platform, the settlement revealed.
“Realistic-looking toy guns can put communities in serious danger and that is why they are banned in New York,” James said in a statement.
“Walmart failed to prevent its third-party sellers from selling realistic-looking toy guns to New York addresses, violating our laws and putting people at risk,” she said.
“The ban on realistic-looking toy guns is meant to keep New Yorkers safe and my office will not hesitate to hold any business that violates that law accountable.”
Walmart must pay $14,000 in penalties and $2,000 in fees under the settlement, the AG’s office said.
That total of $16,000 is a tiny fraction of the approximately $49 million in net income Walmart earned on an average day in the most recent financial quarter.
CNBC has requested comment from Walmart, which neither admitted nor denied the findings by James’ office in its investigation.
As part of the settlement, Walmart is required to prohibit third parties from offering for sale or selling any of the imitation guns covered by the state law to buyers in New York.
“Walmart shall terminate the ability of a third party from being able to list and sell toy guns and imitation weapons on Walmart.com when it has determined that a third party has engaged in conduct” that violates that restriction on three separate occasions, the settlement said.
And “Walmart shall implement and maintain policies and procedures reasonably designed to prevent such third parties from offering for sale, exposing for sale, or selling Prohibited Items on Walmart.com for importation, holding for sale, or distribution to New York,” the settlement says.
